Dr. Christopher G. Goetz, MD
Neurology (Neurology Physician)
1725 W Harrison, #755 Neuroscience Institute Sect Of Movement Disorders
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 478
Licensed in Illinois since 1976, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
IL license 036053565 (first issued 1976; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 478
- Services billed
- 803
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 742 | 426 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 75 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 52 | 52 |
| Established patient office or other outpatient visit, 40-54 minutes | 37 | 35 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Chicago, IL | 923 |
| Amantadine (amantadine hcl) Other prescribers in Chicago, IL | 342 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Chicago, IL | 262 |
| Rasagiline Mesylate | 186 |
| Selegiline Hcl | 178 |
| Entacapone | 174 |
| Donepezil Hcl Other prescribers in Chicago, IL | 113 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Chicago, IL | 106 |
| Ropinirole Hcl Other prescribers in Chicago, IL | 78 |
| Amitriptyline Hcl Other prescribers in Chicago, IL | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $104,043 in research payments for these studies, mostly to the institutions running them.
- Fixed-Dose Trial in Early Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04201093 - Open-label Trial in Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04760769 - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252 - A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186 - Open-label Trial in Parkinson s Disease (PD) (TEMPO-4)
AbbVie Inc. - Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
AbbVie Inc. · Completed · NCT04542499
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.